Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments Aug 11, 2022
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments May 12, 2022
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments Mar 24, 2022
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference Mar 8, 2022
Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial Dec 8, 2021
Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments Nov 12, 2021
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma Oct 27, 2021
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma Sep 16, 2021
